Integrated analysis of circulating tumour cells and circulating tumour DNA to detect minimal residual disease in hepatocellular carcinoma
Open Access
- 5 April 2022
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (4) , e793
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (81872033, 82073327)
This publication has 10 references indexed in Scilit:
- Plasma-only ctDNA-Guided MRD Detection in Patients with CRC—ResponseClinical Cancer Research, 2021
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 2021
- Genome‐wide mutation analysis in precancerous lesions of endometrial carcinomaThe Journal of Pathology, 2020
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast CancerJAMA Oncology, 2020
- Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon CancerJAMA Oncology, 2019
- Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular CarcinomaClinical Cancer Research, 2019
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerJAMA Oncology, 2019
- Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder CarcinomaJournal of Clinical Oncology, 2019
- Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsyProceedings of the National Academy of Sciences, 2019
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004